Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

jakafi

  • Home
  •  
  • jakafi



  • Most Read
  • Latest Comments
  • Pharmaxis shares present untapped value as the drug developer pursues a rare cancer therapy
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Pharmaxis shares present untapped value as the drug developer pursues a rare cancer therapy
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Pharmaxis shares present untapped value as the drug developer pursues a rare cancer therapy
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Pharmaxis shares present untapped value as the drug developer pursues a rare cancer therapy
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Pharmaxis shares present untapped value as the drug developer pursues a rare cancer therapy
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Syntara partners with University of Newcastle and ALLG to reduce blood transfusion dependence in blood cancer patients
    Syntara partners with University of Newcastle and ALLG to reduce blood transfusion dependence in blood cancer patients
    • News

  • Platinum Asset Management sees cancer treatment potential, boosts stake in Syntara to 19.24%
    Platinum Asset Management sees cancer treatment potential, boosts stake in Syntara to 19.24%
    • News

  • Syntara prepares for new clinical trials led by Professor Fiona Wood to restore elasticity into burn scars
    Syntara prepares for new clinical trials led by Professor Fiona Wood to restore elasticity into burn scars
    • News

  • Syntara doses first blood cancer patient for combination treatment of SNT-5505 and ruxolitinib
    Syntara doses first blood cancer patient for combination treatment of SNT-5505 and ruxolitinib
    • News

  • First patients dosed in Phase 2 clinical trials to tackle Parkinson’s disease
    First patients dosed in Phase 2 clinical trials to tackle Parkinson’s disease
    • News

  • Pharmaxis shares present untapped value as the drug developer pursues a rare cancer therapy
    • News

    Pharmaxis shares present untapped value as the drug developer pursues a rare cancer therapy

    In biotech circles, tackling a rare and difficult disease with few patients does not necessarily equate to targeting an unprofitable one.  In the case of fibrotic diseases specialist Pharmaxis (ASX: PXS), its proposed treatment for the rare blood cancer myelofibrosis presents a potential billion dollar-plus market, even though only about 15 in every 1 million

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.